Skip to main content
SpringerLink
Log in

TNFi treatment persistence provides cost offsets

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Merck & Co., USA.

Reference

  • Ziegelbauer K, et al. The impact of non-persistence on the direct and indirect costs in patients treated with subcutaneous tumour necrosis factor-alpha inhibitors in Germany. Rheumatology : 12 Apr 2018. Available from: URL: http://doi.org/10.1093/rheumatology/key099

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

TNFi treatment persistence provides cost offsets. PharmacoEcon Outcomes News 802, 31 (2018). https://doi.org/10.1007/s40274-018-4922-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4922-2

Search

Navigation